Tim Jasper KnotnerusDirector · Chief Executive Officer
4
Filed Oct 7, 2026Period of report Oct 5, 20260002120886-26-000001
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseOct 6, 2026
Common sharesF1
5,000
$8.70
$43.50K
21,823
Direct
PurchaseOct 5, 2026
Common sharesF1
6,000
$8.48
$50.88K
16,823
Direct
Filing footnotes · 2
F1The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
F2Shares held by TJK Life Sciences B.V. ("TJK Life Sciences"). The Reporting Person exercises voting and dispositive power over the shares held by TJK Life Sciences and disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.